Primary Job Title Member of the Board of Directors Primary Organization 
TetraLogic Pharmaceuticals
Location Greater New York Area, United States, North America Regions East Coast Gender Female
LinkedIn View on LinkedIn
Mary Ann Gray is President of Gray Strategic Advisors, LLC which provides strategic advice to both public and private biotechnology companies. Previously, she spent three and a half years with the Federated Kaufmann Fund focusing on both public and private healthcare investments. Prior to joining the Kaufmann Fund, Dr. Gray was a sell-side
biotechnology analyst for nine years with Kidder Peabody, Dillon Read and Raymond James.
Dr. Gray also serves on the board of three public biotechnology companies, Dyax Corp. Acadia Pharmaceuticals and Senomyx Inc. She is lead director, chair of the compensation committee and a member of the nominating and governance committee at Dyax. At Acadia she serves as chairman of the audit committee and also serves on the compensation committee. At Senomyx she is a member of the compensation committee.
Dr. Gray has a Ph.D. in Pharmacology from the University of Vermont where she focused on novel chemotherapeutic agents for the treatment of cancer. She did post-doctoral work at Northwestern University Medical School and Yale University School of Medicine. She held scientific positions at Schering Plough and NeoRx.
Earlier in her career, Dr. Gray managed pre-clinical toxicology studies for the National Cancer Institute through Battelle Memorial Institute and worked in hospital laboratory.
